Moleculin Biotech (MBRX) Stock Price, News & Analysis

Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Phase 3 clinical stage pharmaceutical company in the pharmaceutical preparation manufacturing industry. According to the company’s public statements, Moleculin focuses on advancing a pipeline of therapeutic candidates that address hard-to-treat tumors and certain viral infections. Its work centers on oncology and virology drug candidates that are designed to tackle cancers and pathogens that are resistant to existing therapies.

The company’s lead program is Annamycin, also known by its non-proprietary name naxtarubicin. Moleculin describes Annamycin as a next-generation anthracycline that is highly efficacious and well tolerated in its clinical experience to date, and is designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity that is common with currently prescribed anthracyclines. Annamycin is in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin reports that Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory AML, as well as Orphan Drug Designation for STS lung metastases. The company also states that Annamycin has Orphan Drug Designation for relapsed or refractory AML from the European Medicines Agency (EMA). In addition, Moleculin notes that Annamycin benefits from composition of matter patent protection with a base term extending into the 2040s, subject to potential extensions related to regulatory approvals.

MIRACLE Phase 3 AML Program

A central element of Moleculin’s business is the MIRACLE trial (Moleculin R/R AML AnnAraC Clinical Evaluation), designated as study MB-108. The company describes MIRACLE as a pivotal, adaptive design Phase 2B/3, global, multi-center, randomized, double-blind, placebo-controlled clinical trial. The study evaluates Annamycin in combination with cytarabine (also known as Ara-C), with the combination referred to as AnnAraC, for adult patients with relapsed or refractory AML following induction therapy.

In Part A of MIRACLE, the first 90 subjects are randomized to receive high-dose cytarabine (HiDAC) plus placebo or HiDAC plus one of two Annamycin doses (190 mg/m² or 230 mg/m²). Moleculin explains that the protocol allows for planned unblindings at 45 and 90 subjects to evaluate preliminary primary efficacy (complete remission, or CR) and safety/tolerability across the three arms. Data from Part A are intended to inform the selection of the optimal Annamycin dose for Part B, where additional subjects are randomized to HiDAC plus placebo or HiDAC plus the chosen Annamycin dose.

The company states that the MIRACLE trial is global, with sites in the United States, the European Union and Eastern Europe, and references participation from multiple countries including the U.S., Spain, Italy, Poland, Czechia, Romania, Ukraine, Lithuania and Georgia. Moleculin has reported ongoing enrollment progress and describes MIRACLE as a global approval trial for Annamycin in the R/R AML setting, subject to appropriate regulatory filings and feedback from the FDA and foreign regulators.

Clinical Data and Cardiotoxicity Profile of Annamycin

Moleculin has publicly highlighted the cardiotoxicity profile of Annamycin as a key differentiator relative to existing anthracyclines. The company reports that an independent expert in chemotherapy cardiotoxicity has reviewed data from 90 subjects treated with Annamycin across five clinical trials in AML and STS, including monotherapy and combination regimens with cytarabine at sites in the U.S. and European Union. Based on serial 12-lead ECGs, transthoracic echocardiography with global longitudinal strain analysis, and cardiac biomarker measurements (troponins I and T), the expert concluded there was no evidence of cardiotoxicity in the reviewed subjects, including many treated above the recommended lifetime maximum cumulative anthracycline exposure established by the FDA.

The company emphasizes that Annamycin is being investigated as a potential non-cardiotoxic anthracycline, noting the widespread use of cardiotoxic anthracyclines in oncology and the long-term cardiac risks associated with those agents. Moleculin’s communications describe a growing body of data supporting Annamycin’s lack of observed cardiotoxicity to date in its clinical trials, while also citing previously reported efficacy signals in second-line AML and STS lung metastases.

Expansion of Annamycin into Additional Indications

Beyond AML and STS lung metastases, Moleculin is supporting investigator-initiated and preclinical work to explore Annamycin in other cancers. The company has disclosed agreements for preclinical research at the University of North Carolina at Chapel Hill (UNC) evaluating Annamycin in pancreatic ductal adenocarcinoma (PDAC) models, including comparisons of liposomal Annamycin (L-Annamycin) and free Annamycin versus Doxil and free doxorubicin. Moleculin has also announced a research and material transfer agreement with CIC biomaGUNE in Spain to study intra-arterial delivery of liposomal and free Annamycin in glioblastoma multiforme (GBM) models, compared with Doxil and doxorubicin.

In addition, the company has reported an agreement with Atlantic Health System, Inc. to commence an investigator-initiated Phase 1B/2 single-arm clinical study evaluating Annamycin for third-line advanced pancreatic cancer. Moleculin notes that preclinical data have indicated high affinity and concentration of Annamycin in the pancreas and that upregulation of topoisomerase II, Annamycin’s primary target, is associated with poor survival in pancreatic cancer, which the company views as a rationale for pursuing this indication.

WP1066 Immune/Transcription Modulator Program

Alongside Annamycin, Moleculin is developing WP1066, which it describes as an Immune/Transcription Modulator. According to the company, WP1066 is designed to stimulate the immune response to tumors by inhibiting regulatory T cell activity and by inhibiting key oncogenic transcription factors, including phosphorylated STAT3 (p-STAT3), c-Myc and HIF-1α. These transcription factors are described as important in cancer cell survival and proliferation, angiogenesis, invasion, metastasis and tumor-associated inflammation.

Moleculin has reported externally funded clinical activity with an oral formulation of WP1066. An investigator-initiated Phase 2 trial in combination with radiation for glioblastoma (GBM) is recruiting and treating subjects at Northwestern University. At Emory University, a physician-sponsored Phase 1 trial at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta evaluated WP1066 in children with recurrent malignant brain tumors, including high-grade glioma, diffuse midline glioma (DMG), diffuse intrinsic pontine glioma (DIPG), relapsed medulloblastoma and ependymoma.

The company has highlighted results from this pediatric Phase 1 trial, which showed that WP1066 was administered twice daily over 14 days to determine a maximum feasible dose, with no significant toxicity reported and evidence of STAT3 suppression and anti-tumor immune responses. Moleculin notes that these findings were published in a peer-reviewed journal and that the Emory team has indicated interest in conducting a follow-on Phase 2 trial. The company has also entered into an agreement with Emory to study various intravenous (IV) formulations of WP1066 in preclinical settings with a focus on brain cancers such as GBM.

WP1122 and Antimetabolite Portfolio

In addition to Annamycin and WP1066, Moleculin describes a portfolio of antimetabolites in its pipeline. Among these is WP1122, which the company identifies as a candidate for the potential treatment of pathogenic viruses and certain cancer indications. Public disclosures characterize WP1122 as part of Moleculin’s broader strategy to address both oncology and viral diseases, although detailed clinical-stage data for WP1122 are not provided in the referenced materials.

Regulatory and Corporate Status

Moleculin Biotech, Inc. is incorporated in Delaware and lists its principal executive offices in Houston, Texas, based on its SEC filings. The company’s common stock trades on The Nasdaq Capital Market under the ticker symbol MBRX. In recent filings, Moleculin has reported interactions with Nasdaq regarding continued listing standards. The company disclosed that it received a deficiency notice related to the minimum bid price requirement and later reported that it had regained compliance with that rule after its stock traded at or above the required threshold for a specified period.

Separately, Moleculin has reported that Nasdaq staff issued a delisting determination related to stockholders’ equity and alternative listing criteria. The company has stated its intention to appeal that determination to a Nasdaq hearing panel in order to stay any suspension while the appeal is considered. Moleculin has also disclosed that it implemented a 1-for-25 reverse stock split of its common stock, effective December 1, 2025, with trading continuing on Nasdaq under the existing MBRX symbol but with a new CUSIP number.

Business Model and Development Approach

Based on its public communications, Moleculin’s business model centers on discovering, developing and clinically validating novel small-molecule therapeutics in oncology and virology. The company emphasizes late-stage development of its lead anthracycline Annamycin, along with advancing its immune/transcription modulation platform WP1066 and its antimetabolite portfolio. Moleculin frequently highlights collaborations with academic and clinical institutions, including investigator-initiated clinical trials and grant-funded preclinical research, where the company’s primary contributions are drug supply and certain ancillary services, while institutions cover most other costs through external funding.

Moleculin positions its pipeline around unmet medical needs in hard-to-treat cancers such as relapsed or refractory AML, STS lung metastases, pancreatic cancer, GBM and pediatric brain tumors, as well as in pathogenic viral infections. The company’s disclosures focus on mechanistic rationales, regulatory designations, clinical trial designs and collaborative research as key elements of its strategy.